A groundbreaking injectable formulation of the cancer drug Keytruda is poised to significantly reduce hospital time for thousands of patients across the UK. This innovative approach aims to streamline treatment processes, allowing patients to receive immunotherapy more swiftly and conveniently.
Keytruda: A New Era in Cancer Treatment
Keytruda, also known as pembrolizumab, has been a valuable asset in the fight against various cancers since 2015. Previously administered through intravenous infusion, this life-saving drug can require over an hour in a hospital setting for each treatment session. With the introduction of the injectable version, NHS patients will soon be able to receive their treatment in just minutes.
Shirley Xerxes, an 86-year-old from St Albans, Hertfordshire, was among the first to experience this new delivery method at the Mount Vernon Cancer Centre near Watford. “I was in the chair for a matter of minutes instead of an hour or more,” she shared. “It’s made such a difference and gives me more time to live my life, including spending more time gardening.”
Enhancing Patient Experience and Efficiency
Each year, around 14,000 cancer patients in England begin treatment with Keytruda. The new injectable formulation will be administered either every three weeks as a one-minute injection or every six weeks as a two-minute injection, depending on the type of cancer being treated. This swift administration not only benefits patients but also alleviates the burden on healthcare professionals.
Professor Peter Johnson, the national clinical director for cancer at NHS England, noted the tremendous impact this change could have on patient care. “Managing cancer treatment and regular hospital trips can be really exhausting. If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals,” he explained.
The Science Behind Immunotherapy
Immunotherapy, a field that has transformed cancer treatment, works by enabling the body’s immune system to better identify and attack cancer cells. Cancer cells often employ tactics to evade the immune system, effectively putting on an “invisibility cloak.” Keytruda and similar immunotherapy drugs block these signals, allowing the immune system to recognise and destroy cancerous cells.
This innovative approach has garnered significant attention in the medical community, earning researchers James Allison and Tasuku Honjo the Nobel Prize for Medicine in 2018. Keytruda was one of the first immunotherapy agents approved, initially for skin cancer and later for other types, making it the best-selling prescription drug globally, with projected sales of approximately $30 billion (£22 billion) by 2025.
Implications for the NHS and Beyond
While NHS England has not disclosed the financial details of its agreement with the drug manufacturer Merck Sharp & Dohme (MSD), it is believed that the costs for both the injectable and intravenous forms will be comparable. Keytruda has already generated an estimated $180 billion since its launch, making it one of the most lucrative medicines in history. As patents expire in the coming years, the entry of generic alternatives may further influence its market dynamics.
MSD has emphasised that the new injectable form will not only provide substantial time savings for hospitals but also allow for better resource allocation within the NHS. Critics in the US, including Democratic Senator Elizabeth Warren, have raised concerns about the motivations behind the new formulation, suggesting it may serve to shield the drug from competition. However, MSD maintains that the injectable version offers meaningful benefits for both patients and healthcare facilities.
Why it Matters
The introduction of the injectable Keytruda represents a significant advancement in cancer treatment within the NHS, promising to enhance the quality of life for patients while optimising healthcare resources. By reducing the time spent in hospital settings, this innovation not only fosters a more efficient healthcare system but also allows individuals to reclaim precious moments in their lives. As the NHS continues to adapt and innovate, the potential to deliver treatments more effectively and compassionately remains at the forefront of cancer care.
